Defense from the group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor

Journal of Infectious Diseases

Volumn 203, Issue 11, 2011, Pages 1595-1601

  Huang, Ya Shu ^a   Fisher, Morly ^b   Nasrawi, Ziyad ^a   Eichenbaum, Zehava ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; STREPTOCOCCAL HEMOPROTEIN RECEPTOR; STREPTOCOCCAL HEMOPROTEIN RECEPTOR ANTIBODY; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HUMORAL IMMUNITY; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SECRETIONS; SURVIVAL RATE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; HEMEPROTEINS; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAPERITONEAL; KAPLAN-MEIER ESTIMATE; LACTOCOCCUS LACTIS; MEMBRANE PROTEINS; MICE; PHAGOCYTOSIS; RABBITS; SERUM BACTERICIDAL ANTIBODY ASSAY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINATION;

EID: 79956199290     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir149     Document Type: Article

References (48)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511. (Pubitemid 30452618)
2. Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child Health 2007; 43:203-13. (Pubitemid 46570082)
3. Guilherme L, Fae K, Oshiro SE, Kalil J. Molecular pathogenesis of rheumatic fever and rheumatic heart disease. Expert Rev Mol Med 2005; 7:1-15.
4. Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. Scand J Immunol 2007; 66:199-207. (Pubitemid 47064375)
5. Snider LA, Swedo SE. Post-streptococcal autoimmune disorders of the central nervous system. Curr Opin Neurol 2003; 16:359-65. (Pubitemid 36688305)
6. Snider LA, Swedo SE. PANDAS: current status and directions for research. Mol Psychiatry 2004; 9:900-7. (Pubitemid 39381954)
7. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685-94. (Pubitemid 41505357)
8. Cohen-Poradosu R, Kasper DL. Group A streptococcus epidemiology and vaccine implications. Clin Infect Dis 2007; 45:863-5. (Pubitemid 47580377)
9. Dale JB. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008; 609:53-63.
10. Steer AC, Batzloff MR, Mulholland K, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 2009; 22:544-52.
11. Facklam RF, Martin DR, Lovgren M, et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin Infect Dis 2002; 34:28-38. (Pubitemid 33152662)
12. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 1996; 34:953-8. (Pubitemid 26091514)
13. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962; 89:307-13.
14. Shulman ST, Tanz RR, Dale JB, et al. Seven-year surveillance of North American pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009; 49:78-84.
15. Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet 2001; 358:1334-7. (Pubitemid 33016498)
16. Steer AC, Jenney AW, Kado J, et al. Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr Infect Dis J 2009; 28:477-82.
17. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41:1114-22. (Pubitemid 41429473)
18. Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial. Jama 2004; 292:709-15. (Pubitemid 39062525)
19. Steer AC, Magor G, Jenney AW, et al. emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009; 47:2502-9.
20. Ji Y, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997; 65:2080-7.
21. Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One 2009; 4:e5147.
22. Sabharwal H, Michon F, Nelson D, et al. Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006; 193:129-35. (Pubitemid 43032508)
23. Dale JB, Baird RW, Courtney HS, Hasty DL, Bronze MS. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J Infect Dis 1994; 169:319-23. (Pubitemid 24045590)
24. Yokoyama Y, Harabuchi Y. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol 2002; 63:235-41. (Pubitemid 34462136)
25. McArthur J, Medina E, Mueller A, et al. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect Immun 2004; 72:7342-5. (Pubitemid 39552411)
26. Kawabata S, Kunitomo E, Terao Y, et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001; 69:924-30. (Pubitemid 32109558)
27. Courtney HS, Hasty DL, Dale JB. Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. Infect Immun 2003; 71:5097-103. (Pubitemid 37070752)
28. Rodriguez-Ortega MJ, Norais N, Bensi G, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24:191-7. (Pubitemid 43221703)
29. Turner CE, Kurupati P, Wiles S, Edwards RJ, Sriskandan S. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine 2009; 27:4923-9.
30. Bates CS, Montanez GE, Woods CR, Vincent RM, Eichenbaum Z. Identification and characterization of a Streptococcus pyogenes operon involved in binding of hemoproteins and acquisition of iron. Infect Immun 2003; 71:1042-55. (Pubitemid 36254283)
31. Fisher M, Huang YS, Li X, McIver KS, Toukoki C, Eichenbaum Z. Shr is a broad-spectrum surface receptor that contributes to adherence and virulence in group A streptococcus. Infect Immun 2008; 76:5006-15.
32. Sumby P, Porcella SF, Madrigal AG, et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J Infect Dis 2005; 192:771-82. (Pubitemid 41193074)
33. Beres SB, Sylva GL, Barbian KD, et al. Genome sequence of a serotype M3 strain of group A Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci U S A 2002; 99:10078-83. (Pubitemid 34831175)
34. Bates CS, Toukoki C, Neely MN, Eichenbaum Z. Characterization of MtsR, a new metal regulator in group A streptococcus, involved in iron acquisition and virulence. Infect Immun 2005; 73:5743-53. (Pubitemid 41193009)
35. Quigley BR, Hatkoff M, Thanassi DG, Ouattara M, Eichenbaum Z, Scott JR. A foreign protein incorporated on the Tip of T3 pili in Lactococcus lactis elicits systemic and mucosal immunity. Infect Immun 2010; 78:1294-303.
36. Olive C, Sun HK, Ho MF, et al. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 2006; 194:316-24. (Pubitemid 44116973)
37. Malli E, Tatsidou E, Damani A, et al. Macrolide-resistant Streptococcus pyogenes in Central Greece: prevalence; mechanism and molecular identification. Int J Antimicrob Agents 2010; 35:614-5.
38. Ikebe T, Wada A, Oguro Y, et al. Emergence of clindamycin-resistant Streptococcus pyogenes isolates obtained from patients with severe invasive infections in Japan. Jpn J Infect Dis 2010; 63:304-5.
39. Feng L, Lin H, Ma Y, et al. Macrolide-resistant Streptococcus pyogenes from Chinese pediatric patients in association with Tn916 transposons family over a 16-year period. Diagn Microbiol Infect Dis 2010; 67:369-75.
40. Ardanuy C, Domenech A, Rolo D, et al. Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J Antimicrob Chemother 2010; 65:634-43.
41. Repa A, Grangette C, Daniel C, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003; 22:87-95. (Pubitemid 37357155)
42. Hanniffy SB, Carter AT, Hitchin E, Wells JM. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007; 195:185-93. (Pubitemid 46080050)
43. Buccato S, Maione D, Rinaudo CD, et al. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J Infect Dis 2006; 194:331-40. (Pubitemid 44116975)
44. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002; 20:2816-25. (Pubitemid 34597142)
45. D'Alessandri R, Plotkin G, Kluge RM, et al. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis 1978; 138:712-8. (Pubitemid 9110637)
46. Batzloff MR, Pandey M, Olive C, Good MF. Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res 2006; 35:233-48. (Pubitemid 46020725)
47. Jones T, Allard F, Cyr SL, et al. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 2003; 21:3706-12. (Pubitemid 37338195)
48. Johansson L, Thulin P, Low DE, Norrby-Teglund A. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin Infect Dis 2010; 51:58-65.